Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has a cash flow conversion efficiency ratio of 0.055x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥504.02 Million ≈ $73.75 Million USD) by net assets (CN¥9.15 Billion ≈ $1.34 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Chengdu Kanghong Pharmaceuticals Group C (002773) net asset quality to measure how much of total assets are equity-financed.
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Chengdu Kanghong Pharmaceuticals Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Chengdu Kanghong Pharmaceuticals Group C cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chengdu Kanghong Pharmaceuticals Group Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Solusi Tunas Pratama Tbk
JK:SUPR
|
0.174x |
|
Luster LightTech Co. Ltd. Cl A
SHG:688400
|
N/A |
|
Himadri Speciality Chemical Limited
NSE:HSCL
|
-0.020x |
|
Boyd Group Services Inc.
NYSE:BGSI
|
0.044x |
|
China South Publishing & Media Group Co Ltd
SHG:601098
|
-0.021x |
|
Teleperformance SE
PA:TEP
|
0.220x |
|
WisdomTree Inc.
NYSE:WT
|
0.039x |
|
CorVel Corp
NASDAQ:CRVL
|
0.123x |
Annual Cash Flow Conversion Efficiency for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2025)
The table below shows the annual cash flow conversion efficiency of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see 002773 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥9.27 Billion ≈ $1.36 Billion |
CN¥1.50 Billion ≈ $220.03 Million |
0.162x | -0.71% |
| 2024-12-31 | CN¥8.65 Billion ≈ $1.27 Billion |
CN¥1.41 Billion ≈ $206.60 Million |
0.163x | +4.69% |
| 2023-12-31 | CN¥7.81 Billion ≈ $1.14 Billion |
CN¥1.22 Billion ≈ $178.29 Million |
0.156x | +16.44% |
| 2022-12-31 | CN¥6.91 Billion ≈ $1.01 Billion |
CN¥925.15 Million ≈ $135.38 Million |
0.134x | +65.50% |
| 2021-12-31 | CN¥6.10 Billion ≈ $893.35 Million |
CN¥494.11 Million ≈ $72.30 Million |
0.081x | +70.45% |
| 2020-12-31 | CN¥5.76 Billion ≈ $842.26 Million |
CN¥273.32 Million ≈ $39.99 Million |
0.047x | -72.98% |
| 2019-12-31 | CN¥4.62 Billion ≈ $676.13 Million |
CN¥812.15 Million ≈ $118.84 Million |
0.176x | +104.58% |
| 2018-12-31 | CN¥4.08 Billion ≈ $597.61 Million |
CN¥350.88 Million ≈ $51.35 Million |
0.086x | -60.30% |
| 2017-12-31 | CN¥3.54 Billion ≈ $518.52 Million |
CN¥766.86 Million ≈ $112.22 Million |
0.216x | -25.72% |
| 2016-12-31 | CN¥2.90 Billion ≈ $425.08 Million |
CN¥846.35 Million ≈ $123.85 Million |
0.291x | +52.64% |
| 2015-12-31 | CN¥2.52 Billion ≈ $369.49 Million |
CN¥481.97 Million ≈ $70.53 Million |
0.191x | +5.59% |
| 2014-12-31 | CN¥1.61 Billion ≈ $235.85 Million |
CN¥291.38 Million ≈ $42.64 Million |
0.181x | -24.65% |
| 2013-12-31 | CN¥1.39 Billion ≈ $203.30 Million |
CN¥333.31 Million ≈ $48.77 Million |
0.240x | -5.84% |
| 2012-12-31 | CN¥1.11 Billion ≈ $161.87 Million |
CN¥281.84 Million ≈ $41.24 Million |
0.255x | +41.29% |
| 2011-12-31 | CN¥936.39 Million ≈ $137.02 Million |
CN¥168.86 Million ≈ $24.71 Million |
0.180x | -17.63% |
| 2010-12-31 | CN¥624.85 Million ≈ $91.44 Million |
CN¥136.79 Million ≈ $20.02 Million |
0.219x | +8.98% |
| 2009-12-31 | CN¥539.75 Million ≈ $78.98 Million |
CN¥108.42 Million ≈ $15.87 Million |
0.201x | -- |
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices in China. It develops medicines for ophthalmic, neuropsychiatric, and others. The company was founded in 1996 and is headquartered in Chengdu, China.